Cargando…

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Lung cancer is a devastating disease, with non-small cell lung cancer (NSCLC) being the most common subtype. With the development of novel targeted therapeutics, survival times have continuously improved over the past two decades. In a subset of NSCLC, gene rearrangements of the anap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolle, Elisabeth, Taucher, Valentin, Lindenmann, Joerg, Jost, Philipp J., Pichler, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915291/ https://www.ncbi.nlm.nih.gov/pubmed/33572278 http://dx.doi.org/10.3390/cancers13040699

Ejemplares similares

Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review
por: Smolle, Elisabeth, et al.
Publicado: (2021)

Prediction of Postoperative Clinical Outcomes in Resected Stage I Non-Small Cell Lung Cancer Focusing on the Preoperative Glasgow Prognostic Score
por: Lindenmann, Joerg, et al.
Publicado: (2020)

The Biological and Clinical Relevance of Inhibitor of Growth (ING) Genes in Non-Small Cell Lung Cancer
por: Smolle, Elisabeth, et al.
Publicado: (2019)

Role of Tumor-Associated Neutrophils in the Molecular Carcinogenesis of the Lung
por: Taucher, Elisabeth, et al.
Publicado: (2021)

The Prognostic Long-Term Impact of Chronic Obstructive Pulmonary Disease and Postoperative Mucostasis in Patients with Curatively Resected Non-Small Cell Lung Cancer
por: Lindenmann, Joerg, et al.
Publicado: (2023)

Implications of the Immune Landscape in COPD and Lung Cancer: Smoking Versus Other Causes
por: Taucher, Elisabeth, et al.
Publicado: (2022)

Targeting Signaling Pathways in Epithelial Ovarian Cancer
por: Smolle, Elisabeth, et al.
Publicado: (2013)

Stage-based treatment for thymoma in due consideration of thymectomy: a single-center experience and comparison with the literature
por: Lindenmann, Joerg, et al.
Publicado: (2015)

The History and Development of Hyperbaric Oxygenation (HBO) in Thermal Burn Injury
por: Smolle, Christian, et al.
Publicado: (2021)

Survey of Molecular Mechanisms of Hyperbaric Oxygen in Tissue Repair
por: Lindenmann, Joerg, et al.
Publicado: (2021)

Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer
por: Lindenmann, Joerg, et al.
Publicado: (2020)

Preoperative Peak Oxygen Consumption: A Predictor of Survival in Resected Lung Cancer
por: Lindenmann, Joerg, et al.
Publicado: (2020)

Autophagy, Oxidative Stress and Cancer Development
por: Taucher, Elisabeth, et al.
Publicado: (2022)

A nomogram illustrating the probability of anastomotic leakage following cervical esophagogastrostomy
por: Lindenmann, Joerg, et al.
Publicado: (2020)

Occult solitary submucosal jejunal metastasis from esophageal carcinoma
por: Lindenmann, Joerg, et al.
Publicado: (2005)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Non-Smoking-Associated Lung Cancer: A Distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition
por: Smolle, Elisabeth, et al.
Publicado: (2019)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Hyperbaric Oxygen Therapy and Tissue Regeneration: A Literature Survey
por: Lindenmann, J., et al.
Publicado: (2022)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Current Knowledge about the New Drug Firibastat in Arterial Hypertension
por: Hansen, Emma, et al.
Publicado: (2022)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

SARS-CoV-2-assoziierter Pneumothorax, Pneumomediastinum und Weichteilemphysem. Klinische Implikationen anhand einer Fallserie
por: Mykoliuk, Iurii, et al.
Publicado: (2021)

Massive ventilator-associated pleural empyema
por: Jud, Philipp, et al.
Publicado: (2019)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
por: Chia, Puey Ling, et al.
Publicado: (2014)

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
por: Waterhouse, David M., et al.
Publicado: (2020)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Oulhen, Marianne, et al.
Publicado: (2021)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
por: Zheng, Bei, et al.
Publicado: (2023)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Current Knowledge about Providing Drug–Drug Interaction Services for Patients—A Scoping Review
por: Hammar, Tora, et al.
Publicado: (2021)

Current Status of Long Non-Coding RNAs in Human Cancer with Specific Focus on Colorectal Cancer
por: Smolle, Maria, et al.
Publicado: (2014)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng, Lei, et al.
Publicado: (2018)

Second- and third-generation ALK inhibitors for non-small cell lung cancer
por: Wu, Jingjing, et al.
Publicado: (2016)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_npvso2i5ap0h6cjs1p5uvgb8pt